EUCTR2007-000207-15-BE进行中（未招募）不适用
A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder once-daily (PE capsule via tiotropium/salmeterol HandiHaler®), Tiotropium (18 µg) Inhalation Powder once-daily (via Spiriva® HandiHaler®), Salmeterol (50 µg) Inhalation Powder twice daily (via Multi-Dose Powder Inhaler) and a free combination of Tiotropium (18 µg) Inhalation Powder once-daily (via Spiriva® HandiHaler®) plus Salmeterol (50 µg) Inhalation Powder twice daily (via Multi-Dose Powder Inhaler) following 4-week treatment periods in patients with chronic obstructive pulmonary disease (COPD) - Pharmacokinetics, safety and efficacy of Tiotropium/Salmeterol Inhalation Powder
SCS Boehringer Ingelheim Comm.V0 个研究点目标入组 50 人开始时间: 2008年5月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. All patients must sign an informed consent consistent with ICH-GCP guidelines and local legislations prior to any study-related procedures, which includes medication washout and restrictions.
- •2. All patients must have a diagnosis of COPD and must meet the following criteria:
- •relatively stable* airway obstruction with a post-bronchodilator FEV1 < 80% of predicted normal and post-bronchodilator FEV1 < 70% of post-bronchodilator FVC at Visit 1 (according to GOLD criteria).
- •3. Male or female patients 40 years of age or older.
- •4. Patients must be current or ex-smokers with a smoking history of = 10 pack-years (patients who have never smoked cigarettes must be excluded).
- •5. Patients must be able to perform technically acceptable pulmonary function tests during the study period as required in the protocol.
- •6. Patients must be able to inhale medication in a competent manner from the HandiHaler devices and the multi-dose powder inhaler.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Significant diseases other than COPD. A significant disease is defined as a disease or condition which, in the opinion of the investigator, may either put the patient at risk because of participation in the study or may influence either the results of the study or the patient’s ability to participate in the study.
- •2. Patients with clinically significant abnormal baseline haematology, blood chemistry or urinalysis, if the abnormality defines a significant disease as defined in exclusion criterion No. 1.
- •3. Patients with a recent history (i.e., six months or less) of myocardial infarction.
- •4. Patients with any unstable or life-threatening cardiac arrhythmia requiring intervention or change in drug therapy during the past year.
- •5. Hospitalisation for cardiac failure during the past year.
- •6. Malignancy for which the patient has undergone resection, radiation therapy or chemotherapy within the last five years. Patients with treated basal cell carcinoma are allowed.
- •7. Patients with a history of asthma or atopy, or who have a total blood eosinophil count =600/mm3. A repeat eosinophil count will not be conducted in these patients.
- •8. Patients with a history of life threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis.
- •9. Known active tuberculosis.
- •10. Patients with a history (within the past two years) of and/or active significant alcohol or drug abuse. See exclusion criterion No. 1.
- •11. Patients who have undergone thoracotomy with pulmonary resection. Patients with a history of thoracotomy for other reasons should be evaluated as per exclusion criterion No. 1.
- •12. Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the Screening Visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program that will not be maintained throughout the duration of the study.
- •13. Patients who regularly use daytime oxygen therapy for more than 1 hour per day and in the investigator’s opinion will be unable to abstain from the use of oxygen therapy.
- •14. Patients who have taken an investigational drug within 30 days or six half-lives (whichever is greater) prior to Screening Visit (Visit 1).
- •15. Use of antihistamines (H1 receptor antagonists), anti-leukotrienes or leukotriene receptor antagonists for asthma or excluded allergic conditions. See exclusion criterion No 7.
- •16. Use of cromolyn sodium or nedocromil sodium.
- •17. Use of systemic corticosteroid medication at unstable doses (i.e., less than six weeks on stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day.
- •18. Known hypersensitivity to anticholinergic drugs, ß2-adrenergic drugs, lactose or any other component of the study medication delivery systems.
- •19. Women of childbearing potential not using a highly effective method of birth control. Highly effective methods of birth control are defined as those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner. Female patients will be considered to be of childbearing potential unless surgically sterilised by hysterectomy or bilateral tubal ligation, or post-menopausal for at least two years.
- •20. Treatment with oral beta-adrenergics within 4 weeks prior to Screening Visit (Visit 1) or during the 2-week run-in period.
- •21. Treatment with the lon
研究者
相似试验
进行中（未招募）
不适用
A randomised, open-label, 4-way crossover study to characterize the pharmacokinetics, safety and efficacy of tiotropium and salmeterol after inhalation of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhalation Powder once-daily (PE capsule via tiotropium/salmeterol HandiHaler®), Tiotropium (18 µg) Inhalation Powder once-daily (via Spiriva® HandiHaler®), Salmeterol (50 µg) Inhalation Powder twice daily (via Multi-Dose Powder Inhaler) and a free combination of Tiotropium (18 µg) Inhalation Powder once-daily (via Spiriva® HandiHaler®) plus Salmeterol (50 µg) Inhalation Powder twice daily (via Multi-Dose Powder Inhaler) following 4-week treatment periods in patients with chronic obstructive pulmonary disease (COPD) - Pharmacokinetics, safety and efficacy of Tiotropium/Salmeterol Inhalation PowderChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2007-000207-15-NLBoehringer Ingelheim bv50
已完成
1 期
A study testing wafers containing different doses of dexmedetomidine in healthy volunteers.AgitationMental Health - AnxietyACTRN12622000952741iX Biopharma Pty Ltd14
已完成
不适用
Dietary fat, airway inflammation and bronchodilator response in asthma - Study 2AsthmaACTRN12612000697886John Hunter Hospital25
已完成
3 期
A randomised, open-label, cross-over study to examine the pharmacokinetics, and short-term safety and efficacy of two dosing strategies of raltegravir plus atazanavir in human immunodficiency virus (HIV)-infected patientschronic HIV infectionInfection - Acquired immune deficiency syndrome (AIDS / HIV)ACTRN12609000179235ational Centre in HIV Epidemiology/The University of New South Wales24
进行中（未招募）
1 期
A study comparing the effects of Trimbow to Fostair in COPDEUCTR2018-003113-17-GBThe Medicines Evaluation Unit (MEU) Ltd. (Investigator led study)24